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BACKGROUND & AIMS:

We created and validated a clinical decision support tool (CDST) to predict outcomes of
vedolizumab therapy for ulcerative colitis (UC).

METHODS:

We performed logistic regression analyses of data from the GEMINI 1 trial, from 620 patients
with UC who received vedolizumab induction and maintenance therapy (derivation cohort), to
identify factors associated with corticosteroid-free remission (full Mayo score of 2 or less, no
subscore above 1). We used these factors to develop a model to predict outcomes of treatment,
which we called the vedolizumab CDST. We evaluated the correlation between exposure and
efﬁcacy. We validated the CDST in using data from 199 patients treated with vedolizumab in
routine practice in the United States from May 2014 through December 2017.

RESULTS:

Absence of exposure to a tumor necrosis factor (TNF) antagonist (D3 points), disease duration
of 2 y or more (D3 points), baseline endoscopic activity (moderate vs severe) (D2 points), and
baseline albumin concentration (D0.65 points per 1 g/L) were independently associated with
corticosteroid-free remission during vedolizumab therapy. Patients in the derivation and validation cohorts were assigned to groups of low (CDST score, 26 points or less), intermediate
(CDST score, 27–32 points), or high (CDST score, 33 points or more) probability of vedolizumab
response. We observed a statistically signiﬁcant linear relationship between probability group
and efﬁcacy (area under the receiver operating characteristic curve, 0.65), as well as drug
exposure (P < .001) in the derivation cohort. In the validation cohort, a cutoff value of 26 points
identiﬁed patients who did not respond to vedolizumab with high sensitivity (93%); only the

Abbreviations used in this paper: CDST, clinical decision support tool; CI,
conﬁdence interval; CSFREM, corticosteroid-free remission; ITT, intention
to treat; OR, odds ratio; TNF, tumor necrosis factor; UC, ulcerative colitis;
VDZ, vedolizumab.
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low and intermediate probability groups beneﬁted from reducing intervals of vedolizumab
administration due to lack of response (P [ .02). The vedolizumab CDST did not identify patients with corticosteroid-free remission during TNF antagonist therapy.
CONCLUSIONS:

We used data from a trial of patients with UC to develop a scoring system, called the CDST,
which identiﬁed patients most likely to enter corticosteroid-free remission during vedolizumab
therapy, but not anti-TNF therapy. We validated the vedolizumab CDST in a separate cohort of
patients in clinical practice. The CDST identiﬁed patients most likely to beneﬁted from reducing
intervals of vedolizumab administration due to lack of initial response. ClinicalTrials.gov no:
NCT00783718

Keywords: Prognostic Factor; Response to Treatment; Personalized Medicine; Biologic.

n phase 3 randomized controlled trials, vedolizumab
(VDZ) has been proven efﬁcacious for achieving
clinical remission, corticosteroid-free remission (CSFREM),
and mucosal healing in ulcerative colitis (UC).1 In clinical
practice, pooled rates for clinical response and remission
by week 22 were 51% (95% conﬁdence interval [CI],
43%–61%) and 30% (95% CI, 24%–36%), respectively.2
Studies have identiﬁed predictors of treatment outcomes
for VDZ3; however, the optimal approach to integrating
predictors into routine clinical practice is uncertain.
Waljee et al4 recently developed a machine learning
algorithm for predicting CSFREM with VDZ in UC. This
tool was limited by lack of external validation, need for 6
weeks of therapy before determining risk for treatment
failure, and difﬁculty of bedside implementation. There is
a need for well-validated, drug-speciﬁc, easy-to-use prediction models and clinical decision support tools (CDSTs)
to help guide clinicians in the use of VDZ therapy for UC.
We addressed this gap by deriving a prediction model
and CDST using the GEMINI 1 VDZ clinical trial dataset for
the outcome of CSFREM. We explored correlations between measured VDZ exposure, rapidity in onset of action,
and overall efﬁcacy across predicted probability groups in
the GEMINI 1 trial, and the CDST was subsequently validated in an external routine practice cohort of UC patients
treated with VDZ. To conﬁrm the drug-speciﬁc nature of
this model, we assessed the performance of the CDST for
predicting treatment outcomes in patients with UC treated
with tumor necrosis factor (TNF) antagonist therapy in a
similar routine clinical practice setting. Our intent was to
create a CDST that will help clinicians optimize the use of
VDZ therapy speciﬁcally for individual patients.

I

Materials and Methods
This study is reported according to the TRIPOD
(Transparent Reporting of a multivariable prediction
model for Individual Prognosis Or Diagnosis) statement
and the STROBE (Strengthening the Reporting of
Observational studies in Epidemiology) statement.5,6 All
authors had access to the study results and reviewed and
approved the ﬁnal manuscript.

Data Sources and Participants
Data from the GEMINI 1 trial were used to derive the
prediction model and VDZ-CDST.1 Patients from GEMINI
1 trial (n ¼ 620) were included if they had received VDZ
induction therapy and were assigned to receive VDZ
during maintenance therapy, irrespective of week 6
response status. Placebo-treated patients were excluded.
Data from the Vedolizumab for Health Outcomes in Inﬂammatory Bowel Diseases (VICTORY) Consortium
cohort (VDZ: n ¼ 199; TNF antagonist: n ¼ 123) were
used to externally validate the prediction model and
VDZ-CDST (Supplementary Material).7

Outcome Deﬁnitions
The primary objective was to develop and validate a
VDZ-speciﬁc prediction model and CDST for achieving
CSFREM. Secondary objectives were to assess whether
the VDZ-CDST was able to predict differences in
measured VDZ exposure and onset of action (reductions
in partial Mayo score and fecal calprotectin) within the
GEMINI 1 trial derivation cohort and differences in
colectomy rates and response to VDZ interval shortening
within the VICTORY validation cohort. These secondary
objectives were designed to explore the exposureefﬁcacy relationship for VDZ in UC (Supplementary
Material).
CSFREM in the GEMINI 1 trial was deﬁned as a full
Mayo score of 2, with no subscore >1, and being off
corticosteroids at 52 weeks. CSFREM in the VICTORY
cohort was deﬁned as achieving complete resolution of
UC-related symptoms (rectal bleeding, urgency, stool
frequency), a Mayo endoscopic subscore of 0 or 1, and
being off corticosteroids at 26 weeks. Colectomy status
was also assessed at 26 weeks. We chose 26 weeks as the
time point for validation based on prior clinical observations that patients may need up to 26 weeks to achieve
clinical remission and mucosal healing with VDZ. This
time point was also judged to be the maximal acceptable
duration for clinicians and patients to attempt a therapeutic trial of VDZ.7,8
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Statistical Analysis
What You Need to Know
VDZ Model and CDST Derivation: GEMINI 1 Trial
Cohort. A multivariable logistic regression prediction

model was built from the GEMINI 1 trial cohort data with
CSFREM as the dependent variable. Baseline variables
with P value <.15 on univariable analyses were included
after assessment for collinearity, clinical importance, and
interpretability. A backward model selection approach
with a P value threshold of .15 for inclusion was used.
Interaction terms were assessed individually and
included in the ﬁnal model if they had a P value of <.10
on both the univariable and multivariable analyses. A
sensitivity analysis was performed replacing albumin
with calculated individual-patient VDZ drug clearance
proﬁles based on measured drug exposure to determine
whether this modiﬁcation better predicted CSFREM
(Supplementary Material).9,10
The prediction model was transformed into a CDST,
and prognostic scores were calculated by summing the
points for all predictors present for each patient.11 The
GEMINI 1 trial cohort subjects were split into quartiles
using the VDZ-CDST, and cutoff points were determined for
patients with low (lowest quartile of CSFREM rates), intermediate (middle 2 quartiles of CSFREM rates), or high
(highest quartile of CSFREM rates) probability of achieving
CSFREM with VDZ therapy. We assessed changes in fecal
calprotectin, partial Mayo score, and differences in
measured VDZ concentrations across probability groups
throughout the 52-week GEMINI 1 trial study (exposureefﬁcacy relationship) (Supplementary Material).9,10
To control for type I error when comparing probability groups, a closed test procedure was used. Each of
the pairwise comparisons was conducted at the .05 level,
with no P value adjustments if the hypothesis “all
probability groups equal” was ﬁrst rejected at the .05
level. If the omnibus comparison was not signiﬁcant at
the .05 level, the subsequent comparisons were not
made. Finally, the cutoff points were applied to the
GEMINI 1 trial intention-to-treat (ITT) population to
understand how the probability of achieving CSFREM
with VDZ compared with study participants receiving
placebo and to understand whether the prediction model
was truly predicting outcomes with VDZ or only a patient’s inherent likelihood of responding to any therapy
(ie, placebo) (Supplementary Material).
VDZ Model and CDST Validation: VDZ-Treated VICTORY
Cohort. External validation of the model and CDST was

conducted in the VICTORY cohort. Discriminative ability
was assessed by receiver operating characteristic curve
analysis. Calibration of the model was evaluated using a
calibration curve, a joint hypothesis test using a likelihood ratio, and the Hosmer-Lemeshow goodness-of-ﬁt
test. The overall performance of the models was evaluated with the Nagelkerke R2 and the Brier score
(Supplementary Material).12
The sensitivity, speciﬁcity, positive likelihood ratio,
and negative likelihood ratio of the VDZ-CDST scoring tool

Background
Studies have identiﬁed factors that might be used to
predict responses of patients with ulcerative colitis
to treatment with vedolizumab, but these have not
been systematically analyzed.
Findings
The authors developed and validated a tool, based
on clinical and laboratory values, to identify patients
most likely to enter corticosteroid-free remission
during vedolizumab therapy. Scores associated with
patient drug exposure, time until onset of action, and
achievement of corticosteroid-free remission for
vedolizumab but not tumor necrosis factor antagonist therapy.
Implications for patient care
This study has generated and validated an easy to
use clinical decision support tool speciﬁc to vedolizumab to help clinicians optimize the treatment of
individual patients with ulcerative colitis.

to identify patients with a low or high probability of
achieving CSFREM or requiring colectomy were calculated
after grouping patients into 3 groups according to predicted risk. In UC patients who underwent VDZ interval
shortening for insufﬁcient response (n ¼ 28), we assessed
whether response to VDZ interval shortening varied
across VDZ-CDST predicted probability groups. The decision to undergo shortening was made by providers
without prior knowledge of the VDZ-CDST scoring tool.
VDZ-CDST Drug-Speciﬁc Assessment: TNF Antagonist–
Treated VICTORY Cohort. The VDZ-CDST cutoff points

were applied to patients treated with TNF antagonists
in the VICTORY cohort. The proportion of TNF
antagonist–treated UC patients who achieved CSFREM
or required colectomy by week 26 across the VDZCDST–deﬁned probability groups was compared to the
proportion of VDZ-treated UC patients who achieved
CSFREM or required colectomy by week 26 within
deﬁned probability groups.

Results
Patient Characteristics
Of the 437 VDZ-treated UC patients within the VICTORY
cohort, 85 were excluded for missing baseline albumin
values, and 153 were excluded because they had no endoscopic follow-up after starting VDZ. There were no signiﬁcant differences in the VICTORY cohort patients included or
excluded from the current analyses (Supplementary
Table 1). Compared with the VICTORY cohort, participants
in the GEMINI 1 trial derivation cohort had shorter disease
duration (P < .01), were less often exposed to prior TNF
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Table 1. Comparison of Demographics Between the GEMINI
1 and the VICTORY Cohorts
GEMINI 1
Trial Cohort

VICTORY
Cohort

Vedolizumab Vedolizumab
Validation
Derivation
Cohort
Cohort
P
(n ¼ 199) value
(n ¼ 620)
Female
Smoker (never)
Age, y
Body mass index, kg/m2
Disease duration, y
Disease duration <2 y
Prior hospitalization
Prior TNF antagonist
exposure
Prior TNF antagonist failure
Extensive baseline disease
Baseline moderate
endoscopic disease
Baseline albumin, g/L
Concomitant corticosteroids
only
Concomitant IMMs only
Concomitant corticosteroids
and IMMs

256 (41)
380 (61)
40.1  13
25.1  5.6
5.0 (2.3–9.1)
120 (20)
211 (34)
311 (50)

104 (52)
144 (72)
41.5  17.3
25.3  5.83
6.0 (2–12)
31 (16)
55 (28)
135 (68)

<.01
<.01
.23
.66
<.01
.25
.10
<.01

266 (43)
308 (50)
278 (45)

117 (59)
112 (56)
126 (63)

<.01
.12
<.01

37  4.96
226 (36)

39.4  5.41
69 (35)

<.01
.67

114 (18)
99 (16)

36 (18)
49 (25)

1.00
<.01

Values are n (%), mean  SD, or median (interquartile range).
IMM, immunomodulator; TNF, tumor necrosis factor; VICTORY, Vedolizumab
for Health Outcomes in Inﬂammatory Bowel Diseases.

antagonist therapy (P < .01), more often had severe disease
on baseline endoscopy (P < .01), and had lower baseline
albumin concentrations (P < .01) (Table 1).

antagonist exposure (no vs yes), (3) baseline endoscopy
(moderate vs severe), (4) baseline albumin (absolute
value), and (5) sex (female vs male). Sex was observed to
have a signiﬁcant relationship to VDZ clearance (P <
.001)13 and was deemed an indirect predictor of treatment
outcomes through correlation with the known covariates
of drug clearance: height and weight. Accordingly, sex was
dropped from the model. Baseline characteristics for patients with short (<2 years) or longer (2 years) disease
duration are described in Supplementary Table 3. Patients
with longer disease duration were more likely to have
been exposed to TNF antagonists before initiation of VDZ
therapy (53% vs 38%). Despite this observation, patients
with longer disease duration were more likely to respond
to VDZ. This ﬁnding is of interest because multiple studies
have documented a relatively poor prognosis for the use of
biologics in patients who have previously had TNF antagonist failure. Therefore, this variable was thought to be a
true predictor and was retained in the model. The other 3
variables have been previously identiﬁed in the literature
and were deemed clinically and biologically relevant.3
The ﬁnal model equation is as follows (Table 2):
Y ¼  3:7038
þ ½0:2820 if no prior TNF antagonist exposure
þ ½0:2622 if disease duration  2 years
þ ½0:1847 if baseline endoscopy activity is moderate
þ ½0:0647  baseline albumin concentration in g=L
An example calculation
Supplementary Material.

is

provided

in

the

Model Performance and Validation
Variable Selection
Factors signiﬁcantly (P < .05) associated with
increased probability of achieving CSFREM with VDZ
were disease duration (odds ratio [OR], 1.04 per year),
no previous TNF antagonist exposure (OR, 1.84), no
previous TNF antagonist failure (OR, 1.88), baseline
endoscopic activity (moderate vs severe: OR, 1.57),
baseline stool frequency (nonsevere [partial Mayo score
0–2] vs severe [partial Mayo score 3]: OR, 1.70), and
baseline albumin (OR, 1.08) (Supplementary Table 2).
Disease duration was transformed into a binary categorization (2 years vs <2 years), and previous TNF
antagonist exposure was used instead of previous TNF
antagonist failure for further model building. Baseline
endoscopy was used as a metric for disease activity
instead of stool frequency because it was considered
more objective (Supplementary Material).

Model Building
Variables identiﬁed for potential inclusion were (1)
disease duration (2 years vs <2 years), (2) previous TNF

The discrimination ability in the derivation cohort
was 0.65 and on external validation it was 0.64 (95% CI,
0.50–0.77). During external validation the model
explained approximately 20.8% of variation (Nagelkerke
R2 ¼ 0.10; Brier score 0.18, maximum Brier score 0.22).
There was poor calibration (likelihood ratio c2 ¼ 16.18,
df ¼ 2, P < .001; Hosmer-Lemeshow goodness-of-ﬁt c2 ¼
17.99, df ¼ 4, P < .01) (Supplementary Figure 1). The
calibration slope, however, showed no evidence of
overﬁtting, and the effects of the predictors were therefore similar in the development and validation cohorts.

Clinical Decision Support Tool
Performance of the CDST in the derivation cohort is
described in Supplementary Tables 4-6. Among the ITT
population of the GEMINI 1 trial, the difference in clinical
remission rates between VDZ and placebo at week 6 was
incrementally higher according to stratiﬁcation into low
probability (26 points; VDZ 8.5% vs placebo 3.3%;
difference 5.2%), intermediate probability (>26 to 32
points; VDZ 16% vs placebo 4.7%; difference 11.3%),
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Table 2. Final Multivariable Model for Corticosteroid-Free
Remission With VDZ After 52 Weeks of Therapy
Variable

Odds ratio

95% CI

Previous TNF antagonist
exposure (no vs yes)
Disease duration (2 y vs <2 y)
Baseline endoscopy (moderate vs
severe)
Baseline albumin

1.758

1.194–2.587

1.689
1.447

1.018–2.803
0.991–2.114

1.067

1.024–1.112

CI, conﬁdence interval; TNF, tumor necrosis factor; VDZ, vedolizumab.

and high probability (>32 points) of response to VDZ
(VDZ 25.4% vs placebo 8.8%; difference 16.6%). Using
baseline week 0 values for CDST calculation in rerandomized week 6 responders, a similar incremental
beneﬁt in treatment effect size was seen for CSFREM at
week 52 between the low probability (VDZ 28.2% vs
placebo 10.5%; difference 17.7%), intermediate probability (VDZ 35.7% vs placebo 15.2%; difference 20.5%),
and high probability (VDZ 55.4% vs placebo 17.1%;
difference 38.3%) groups.
In the VICTORY cohort, a score of 26 had a high
sensitivity (93%; 95% CI, 79%–98%) and a good negative
likelihood ratio (0.50; 95% CI, 0.16–1.61) for identifying
patients less likely to achieve CSFREM with VDZ (Figure 1,
Table 3). Poor discriminative performance for the VDZCDST was observed in the TNF antagonist–treated patients from the VICTORY cohort (Figure 1, Supplementary
Table 7). Rates of CSFREM were higher for VDZCDST–predicted high-probability VDZ-treated patients
(32%) than for the VDZ-CDST–predicted high-probability
TNF antagonist–treated patients (23%). Rates of CSFREM
were lower for the VDZ-CDST–predicted low-probability

VDZ-treated patients (12%) than for the VDZ-CDST–predicted low-probability TNF antagonist–treated patients
(21%).

VDZ Drug Exposure-Efﬁcacy Relationships
A statistically signiﬁcant linear trend was observed
for VDZ concentrations within the GEMINI 1 trial derivation cohort when stratiﬁed by the CDST (Figure 2,
Supplementary Table 4). The percent reduction in fecal
calprotectin at week 6 was 20% in the low-probability
group compared with 49% and 56% in the intermediate- and high-probability groups. By week 30, patients in
the low-probability group had achieved a 55% reduction
in fecal calprotectin compared with baseline values.
There were also statistically signiﬁcant differences in
change from baseline of partial Mayo score across 3
probability groups in the GEMINI 1 trial at all visits from
week 2 to week 42, and week 52, based on closed test
procedure (Figure 3, Supplementary Table 5).
In the VICTORY cohort, a clinical response (>50%
reduction in symptom activity) to VDZ interval shortening was seen in 46% (n ¼ 10 of 22) of patients classiﬁed as low or intermediate probability of response
using the CDST. However, among patients undergoing
VDZ interval shortening classiﬁed as high probability
using the CDST (n ¼ 6), none achieved a clinical response
to VDZ interval shortening (P ¼ .024).

Discussion
We derived and validated a VDZ-speciﬁc multivariable prediction model and CDST capable of predicting
differences in measured VDZ drug exposure, onset of

Figure
1. Prognostic
CDST with stratiﬁed treatment outcomes in the
VICTORY cohort.
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Table 3. Diagnostic Performance of Clinical Decision Support Tool in the VICTORY Cohort Among Vedolizumab-Treated
Patients

26 points
Corticosteroid-free remissiona at 26 wk
Colectomy-free at 26 wk
32 points
Corticosteroid-free remissiona at 26 wk
Colectomy-free at 26 wk

Sensitivity
(95% CI) (%)

Speciﬁcity
(95% CI) (%)

Positive likelihood
ratio (95% CI)

Negative likelihood
ratio (95% CI)

93 (79–98)
88 (83–92)

15 (10–21)
29 (8–58)

1.08 (0.97–1.21)
1.23 (0.88–1.73)

0.50 (0.16–1.61)
0.42 (0.17–1.04)

51 (35–67)
37 (30–44)

68 (60–75)
71 (42–92)

1.59 (1.09–2.31)
1.29 (0.55–3.01)

0.72 (0.52–1.00)
0.89 (0.62–1.26)

CI, conﬁdence interval; VICTORY, Vedolizumab for Health Outcomes in Inﬂammatory Bowel Diseases.
a
Remission deﬁned as full Mayo score of 2 points with no subscore >1 point and being off steroids.

action, and VDZ treatment effectiveness, as well as
identifying patients potentially most likely to beneﬁt
from VDZ interval shortening to optimize response. At a
cutoff of 26 points the tool is sensitive for identifying
patients who will not respond to VDZ. With increasing
score there is increased conﬁdence in expectation of
achieving remission with VDZ in UC, with the greatest
conﬁdence achieved at a cutoff of 32 points. When
applied to a TNF antagonist–treated observational cohort
in a routine clinical practice setting, the VDZ-CDST was
not able to predict differences in treatment effectiveness,
conﬁrming the drug-speciﬁc prediction of this VDZ-CDST.

Four predictors for CSFREM with VDZ were identiﬁed
(1) previous TNF antagonist exposure, (2) baseline
endoscopic activity, (3) baseline albumin, and (4) disease
duration. Previous TNF antagonist exposure and severe
disease have been shown to be consistent predictors of
reduced effectiveness for VDZ in clinical practice across
multiple cohorts.3 Albumin is the main determinant of
VDZ clearance, and a correlation between VDZ exposure
and efﬁcacy has been observed in post hoc analyses of
the GEMINI 1 trial.9,10 A novel observation was that
longer disease duration was associated with improved
effectiveness of VDZ. In the GEMINI 1 trial derivation

Figure 2. Prognostic CDST with stratiﬁed VDZ concentrations in the GEMINI 1 trial. Three-group statistical comparisons at
each time point done using nonparametric testing (Kruskal-Wallis). *P < .05, **P < .01, ***P < .001. aAll values in the table are
median VDZ concentration (interquartile range) (mg/mL); postdose concentration was measured 2 hours after dosing. bLow
probability; 26 points in the CDST model at baseline. cIntermediate probability; >26 to 32 points in the CDST model at
baseline. dHigh probability; >32 points in the CDST model at baseline. PK, pharmacokinetics.
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Figure 3. Changes in (A)
partial Mayo score and (B)
fecal calprotectin in the
GEMINI 1 trial cohort
stratiﬁed by CDST. Statistical comparisons at each
time point for partial Mayo
score was done by
ANOVA with type I error
controlled based on a
closed test procedure;
fecal calprotectin statistical analysis was done using nonparametric testing
(Kruskal-Wallis). *P < .05,
**P < .01, ***P < .001 for
both. aAll values in the table are least-squares (LS)
mean partial Mayo score
(PMS) (with standard error
in parentheses). bLow
probability; 26 points in
the CDST model at baseline. cIntermediate probability; >26 to 32 points in
the CDST model at baseline. dHigh probability; >32
points in the CDST model
at baseline. eAll values in
the table are median
percent change in fecal
calprotectin (interquartile
range).

December 2020

cohort, patients with longer disease duration more often
had prior exposure to TNF antagonists. It may have been
anticipated that patients with longer disease duration
would therefore be less likely to respond to VDZ; however, the opposite was seen. The biological rationale for
this is unclear, although it could be speculated that
chronic inﬂammation in those with longer disease
duration results in continuous inﬂammatory signaling
causing cytokine-based signaling pathways to become
refractory to further stimuli, or that resident proinﬂammatory T cells are exhausted from chronic stimuli. In
other chronic autoimmune conditions, T cell exhaustion
has been associated with a good prognosis.14 This ﬁnding
does not imply that clinicians should wait until a patient
has longer disease duration to start VDZ, but rather that
among patients with a chronic course, VDZ may have
improved effectiveness.
We observed an exposure-efﬁcacy relationship across
model-derived prognostic groupings that may be related
to differences in drug disposition. An exposure-efﬁcacy
relationship for VDZ induction has been observed in
UC,10 and post hoc analyses of the GEMINI 1 trial have
indicated that patients with higher VDZ trough concentrations had higher deep remission rates at 52 weeks.15
Despite these associations, clinicians are unable to predict at baseline who may beneﬁt from early therapeutic
drug monitoring with attempts at dose optimization
through interval shortening. We observed a signiﬁcant
trend in increasing exposure-efﬁcacy relationships
across the low-, intermediate-, and high-probability
groups with the VDZ-CDST. Furthermore, a clinical
response to VDZ interval shortening was only observed
in the low- to intermediate-probability group within the
VICTORY cohort, presumably because these patients had
lower trough concentrations than patients in the highprobability group. Although trough VDZ concentration
testing was not routinely performed in the VICTORY
cohort, these data help support the potential use of the
VDZ-CDST to identify at baseline which patients are
likely to have lower VDZ trough concentrations and are
thus potentially most likely to beneﬁt from early proactive therapeutic drug monitoring with VDZ interval
shortening or upfront dose optimization strategies.
The ongoing Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis (ENTERPRET) trial
(NCT03029143) will evaluate higher doses vs standard
doses of VDZ and will help inform our understanding of
the role of dose optimization in UC.
One of the main limitations with prior prediction
model work is that it remains unclear whether identiﬁed
predictors in those models are speciﬁc to the drug being
assessed or are global markers of improved responsiveness to all biologics. In our study, we addressed this
gap and observed that the VDZ-CDST was not able to
predict treatment effectiveness with TNF antagonist
therapy for UC patients in routine clinical practice.
Among patients deemed to have low probability of
response based on the VDZ-CDST, we observed a

Vedolizumab Prediction for Ulcerative Colitis 2959

CSFREM rate of 21% among those treated with TNF
antagonist therapy, compared with 12% for patients
treated with VDZ therapy. In contrast, among patients
deemed to have high probability of response based on
the VDZ-CDST, we observed a CSFREM rate of 25%
among those treated with TNF antagonist therapy,
compared with 32% for patients treated with VDZ
therapy. This would suggest that patients with a low
probability of response might be more appropriately
treated with TNF antagonist therapy, and those with a
high probability are the best candidates for VDZ therapy.
Among patients classiﬁed as having intermediate probability of response, the rates of CSFREM and colectomy
were comparable between those who received TNF
antagonist or VDZ therapy. For these patients, a careful
discussion is warranted that should take into consideration the broader literature for comparative effectiveness and comparative safety when determining optimal
treatment selection.
Our study has several strengths, including external
validation in an independent, real-world dataset derived
from multiple sites, ease of use in routine clinical practice, the ability to screen for patients who are less likely
to achieve key outcomes (CSFREM) and more likely to
require colectomy, and the drug-speciﬁc prediction of
our CDST. There also are several limitations to our study.
The lower bound of the conﬁdence interval for the performance reached 0.5, suggesting that model discrimination may not be ideal. Further validation will therefore
be needed to understand external validity on additional
cohorts. Prospective validation will also be needed for
the observation regarding interval-shortening beneﬁts
being limited to the low-probability cohort, ideally in a
randomized, controlled trial setting. Caution should be
taken when interpreting comparisons of subgroups to
placebo recipients within the ITT population. The negative likelihood ratio of the VDZ-CDST predicts an
approximate 15% reduction in effectiveness and posttest
odds of achieving the outcome (CSFREM) in the lowprobability group,16 but this is likely to be further
modiﬁed by the ability of clinicians to achieve these
outcomes (through enhanced monitoring and care
pathways), irrespective of treatment assignment. Further
work will need to be done to understand how care
pathways integrated with therapeutic CDSTs affect
overall probabilities of achieving key outcomes.
In conclusion, we have derived and externally validated a prediction model and CDST for achieving CSFREM
with VDZ in UC. The VDZ-CDST was observed to have a
high sensitivity for identifying patients with a latency of
onset for response, who were less likely to achieve
CSFREM with VDZ and were more likely to require
colectomy while on VDZ. Furthermore, the CDST was
observed to predict treatment effectiveness with VDZ but
not TNF antagonist therapy, conﬁrming its drug-speciﬁc
use. We have made several key novel observations
regarding VDZ exposure-efﬁcacy relationships, and the
use of this VDZ-CDST in the clinical setting will likely help
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to better guide the decision-making process for choosing
VDZ as a therapeutic option and monitoring or adjusting
therapy over time. To aid in the integration of this tool in
clinical practice, an online tool is available to providers at:
https://rme.arche.services/curriculum/a26dcdf0-00c34209-a67c-b4d4abe02f32. This learning health platform
will allow the user to gain Continuing Medical Education
credits for navigating through a search and learn educational platform which includes the CDST presented here.
We anticipate this educational platform will help to
streamline the integration of guidelines, evidence-based
best practices, and all decision support tools as they
become available over time.

Supplementary Material
Note: To access the supplementary material accompanying this article, visit the online version of Clinical
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Supplementary Material and Methods
Data Source
GEMINI 1 trial data were collected as part of the
phase 3 clinical trial (NCT00783718) with corresponding
ethics/institutional review board approval. The VICTORY
consortium dataset was collected after ethics/institutional review board approval at all participating sites.

Data Source: VICTORY Consortium
The VICTORY Consortium is a multicenter collaborative research group in which patient demographics, disease characteristics, and treatment outcomes are pooled
for inﬂammatory bowel disease (IBD) patients treated
with biologics. Institutional review board approval was
obtained from each site for ongoing retrospective data
collection and transfer. Data were collected individually
by sites using a standardized data collection form and
transferred (after de-identiﬁcation) to the coordinating
site (University of California, San Diego) for data
compilation and analysis.

Model and Clinical Decision Support Tool
Sensitivity Analyses in GEMINI 1 Trial for VDZ
Exposure-Efﬁcacy Relationships
Albumin has previously been shown to be the strongest predictor of exposure-efﬁcacy relationships for
vedolizumab (VDZ) in ulcerative colitis (UC); however,
albumin does not explain the entirety of VDZ exposure
variability.8,9 Before ﬁnalizing the model for external
validation, a sensitivity analysis was performed by
replacing albumin with calculated VDZ clearance proﬁles
for GEMINI 1 trial participants.8,9 Performance of this
model within the GEMINI 1 trial derivation cohort was
slightly better than the original model that included albumin (area under the receiver-operating characteristic
curve [AUC] 0.69 vs 0.65). A baseline prediction model is
not currently available for predicting VDZ exposure over
time, and therefore clearance could not be readily
substituted for albumin in the ﬁnal prediction model.
Albumin was therefore retained for external validation of
the model in the VICTORY Consortium dataset.

GEMINI 1 Trial VDZ Concentration
Assessments
VDZ concentrations were assessed in the GEMINI 1
trial using serum samples with a direct VDZ capture
pharmacokinetic assay. A sandwich enzyme-linked
immunosorbent assay was used for quantifying VDZ in
human serum. Serum concentrations of VDZ were
determined by QPS in accordance with Good Laboratory
Practice. The lower limit of detection was 0.125 mg/mL.
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Time points for trough concentration assessments taken
30 minutes before VDZ infusions were weeks 0, 2, 6, 22,
and 46. Additional concentration assessments were
taken at weeks 4, 14, 38, and 52. Time points for peak
concentration assessments taken 2 hours postinfusion
were weeks 0, 2, 6, 22, and 46. Differences in median
concentrations at each time point across the 3 probability groups were ﬁrst assessed using non-parametric
testing (Kruskal-Wallis), and then pairwise comparisons were done for each group at each time point.

GEMINI 1 Trial Fecal Calprotectin Assessments
Fecal calprotectin was assessed in the GEMINI 1 trial
using the CAL0100 test kit. Time points for assessments
were weeks 0, 6, 30, and 52. Differences in median
concentrations at each time point across the three
probability groups were ﬁrst assessed using nonparametric testing (Kruskal-Wallis), and then pairwise comparisons were done for each group at each time point.

GEMINI 1 Intention-to-Treat Sensitivity
Analyses
Intention-to-Treat Induction Analysis. In accordance
with an intent-to-treat approach, the intention-to-treat
(ITT) population for the induction study consisted of
all randomized patients in the GEMINI 1 trial cohort who
received any amount of blinded study drug during induction treatment.
ITT Maintenance Analysis. In accordance with an
intent-to-treat approach, the ITT population for the
maintenance treatment consisted of all rerandomized
patients randomized as week 6 responders who received
VDZ during induction treatment and then received any
amount of study drug in the maintenance phase.

Model Validation VICTORY Consortium
External validation of the model was conducted in the
VICTORY Consortium cohort. Discriminative ability was
assessed by receiver-operating characteristic curve
analysis and is presented as AUC. An AUC value of 0.5
denotes that the model does not discriminate any better
than random guessing and 1 denotes perfect discrimination. Calibration of the model applied to the external
validation cohort was evaluated in multiple ways. The
observed event rates and predicted risk were graphically
assessed by a calibration curve. The intercept (calibration-in-the-large) assessed whether the overall predicted
event rate matches the observed rate, and should ideally
be zero, indicating no systematic difference in observed
predicted rates. The calibration slope gives an indication
of how over- or under-ﬁt the model is, and should ideally
be 1, indicating no overﬁtting. A joint hypothesis test of
perfect calibration using a likelihood ratio test was
evaluated as an overall test of calibration. This test is
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more sensitive to potential miscalibration than the
Hosmer-Lemeshow goodness-of-ﬁt test, which is also
shown for comparison after splitting the sample into
quintiles. This test assesses whether or not the observed
event rates match expected event rates in subgroups of
the model population, with P values <.05 indicating evidence of poor ﬁt for both calibration tests. The overall
performance of the models was evaluated with the
Nagelkerke R2 and the Brier score. Nagelkerke R2 is a
measure between 0 and 1, with 0 denoting that the
model does not explain any variation and 1 denoting that
it perfectly explains the observed variation in outcomes.
The Brier score is a measure of prediction error with the
mean squared difference between the predicted probability and the actual outcome, and values range from
0 (perfect prediction) to 0.25 (a noninformative
model).10

Results
Variable Selection
A binary categorization was chosen for disease
duration (2 years vs <2 years) because nonlinearity
was observed for the association between disease
duration and corticosteroid-free remission, and a binary
categorization was thought to be easier to interpret and
apply clinically. Previous tumor necrosis factor (TNF)
antagonist exposure was used instead of previous TNF
antagonist failure, given the inability to accurately classify failure subtypes in routine practice and similarity in
signiﬁcance between these variables. Baseline endoscopy
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was used as a metric for disease activity instead of
baseline stool frequency, given the subjectivity in stool
frequency assessment in routine practice, the observation that the signiﬁcance for stool frequency was being
driven by the comparison of severe (Mayo score stool
frequency 3) vs inactive (Mayo score stool frequency 0)
disease, the inclusion of endoscopic disease activity as an
endpoint for the model, and observed collinearity between baseline endoscopy and baseline stool frequency
(P < .01). Current or prior smoking was further investigated as individual variables instead of as a composite
variable, when separating this into current smokers vs
nonsmokers and prior smokers vs nonsmokers, it was
found to not meet the thresholds for inclusion and was
therefore excluded before the second step of model
building.

Model Equation Example
A 35-year-old man with UC is being considered for
VDZ therapy. His UC was diagnosed 15 months prior, and
he had no prior TNF antagonist exposure. Baseline
endoscopy is performed and is notable for the absence of
vascular pattern, marked erythema, and friability,
without ulcers or spontaneous bleeding (Mayo endoscopic subscore 2). Baseline lab results are notable for an
albumin of 40 g/L (4 g/dL).
This patient’s model calculation ¼
 3:7038 þ ½0:2820 þ ½0:1847
þ ½0:0647  40 ¼  0:7464
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Supplementary Figure 1. The calibration plot compares the predicted risk for all patients to their expected risk. The ideal line
(gray) shows perfect calibration (ie, predicted risk is equal to observed risk). The nonparametric line (dashed, gray) shows the
risk for patients over the entire range of risks predicted by the model. The grouped observations (triangles) are the average
risks within each quintile group. The calibration intercept (calibration-in-the-large) and slope were estimated from the calibration curve. The calibration-in-the-large compares the systematic difference between the average observed risk and predicted risk and should ideally be equal to 0, indicating no systematic difference. The calibration-in-the-large estimate is –0.674
(95% conﬁdence interval, –1.379 to 0.031) for the current model. The calibration slope gives an indication of overﬁtting and
should ideally be equal to 1, indicating no overﬁtting or underﬁtting. Its estimate is 0.999 (95% conﬁdence interval, 0.029 to
1.968) for the current model. A format test of calibration can be done by a likelihood ratio test so that the intercept is 0 and
slope is 1. This test conﬁrms that the model predicts risks approximately twice as large as observed on the odds scale
(exp(0.674) ¼ 1.96) (likelihood ratio c2 ¼ 16.18, df ¼ 2, P ¼ .00031), conﬁrming model miscalibration.
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Supplementary Table 1. Comparison of Demographics
Between the VICTORY Cohorts
Included in Validation

Supplementary Table 2. Univariable Analyses for
Corticosteroid-Free Remission
After 52 Weeks of Vedolizumab in
the GEMINI 1 Trial Cohort

VICTORY Consortium
Univariable
VedolizumabEntire
Treated
VedolizumabValidation
Treated Cohort
P
Cohort
(N ¼ 352)a
value
(n ¼ 199)
Female
Smoker (never)
Age, y
BMI, kg/m2
Disease duration, y
Disease duration <2 y
No prior hospitalization
Prior TNF antagonist
exposure
Prior TNF antagonist
failure
Extensive baseline
disease
Baseline moderate
endoscopic disease
Baseline albumin, g/L
Concomitant CS only
Concomitant IMMs only
Concomitant CS and
IMMs

184 (52)
256 (73)
41.6  17.3
25.6  5.77
6.0 (2–12)
54 (16)
93 (26)
231 (66)

104 (52)
144 (72)
41.5  17.3
25.3  5.83
6.0 (2–12)
31 (16)
55 (28)
135 (68)

1.00
.92
.95
.56
1.00
1.00
.77
.64

194 (55)

117 (59)

.42

210 (60)

112 (56)

.47

237 (67)

126 (63)

.35

39.1  5.54
118 (34)
50 (14)
73 (21)

39.4  5.41
69 (35)
36 (18)
49 (25)

.54
.78
.27
.37

Values are n (%), mean  SD, or median (interquartile range).
BMI, body mass index; CS, corticosteroid; IMM, immunomodulator; TNF,
tumor necrosis factor; VICTORY, Vedolizumab for Health Outcomes in Inﬂammatory Bowel Diseases.
a
Includes patients who were ultimately excluded for lack of endoscopic follow-up.

Baseline variable
Age
Sex (female vs male)
Ethnicity (other vs non-Hispanic/Latino)
Race (non-white vs white)
Smoker (current/previous vs nonsmoker)
Smoker (current vs nonsmoker)
Smoker (previous vs nonsmoker)
BMI
Disease duration (continuous)
Disease duration (5 y vs <5 y)
Disease duration (2 y vs <2 y)
EIM (no vs yes)
Prior hospitalization (no vs yes)
Previous TNF antagonist exposure (no vs yes)
Previous TNF antagonist failure (no vs yes)
Concomitant corticosteroids (no vs yes)
Concomitant immunomodulator (no vs yes)
Baseline severe disease, full Mayo score (<10 vs
10)
Baseline full Mayo score
Baseline partial Mayo score
Baseline rectal bleeding Mayo score (1 vs 0)
Baseline rectal bleeding Mayo score (2 vs 0)
Baseline rectal bleeding Mayo score (3 vs 0)
Baseline stool frequency Mayo score (0–2 vs 3)
Baseline stool frequency Mayo score (1 vs 0)
Baseline stool frequency Mayo score (2 vs 0)
Baseline stool frequency Mayo score (3 vs 0)
Baseline endoscopy (moderate vs severe)
Baseline albumin
Baseline albumin (>35 g/L vs 35 g/L)
Baseline fecal calprotectin

Odds
ratio

P
value

1.00
1.34
0.78
0.82
0.72
0.78
0.71
1.03
1.04
1.28
1.49
1.03
1.21
1.84
1.88
0.99
0.72
1.62

.958
.119
.549
.450
.091
.854
.413
.046
.017
.192
.107
.890
.352
.001
.001
.952
.085
.023

0.91
0.94
1.37
1.70
1.92
1.70
1.52
1.25
0.75
1.57
1.08
1.88
1.00

.079
.246
.717
.292
.209
.005
.010
.409
.015
.016
<.001
.002
.939

BMI, body mass index; EIM, extraintestinal manifestation; TNF, tumor necrosis
factor.
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Supplementary Table 3. Baseline Differences in
Demographics Between Longer
Disease Duration (2 y) and
Shorter Disease Duration (<2 y)
Patients in the GEMINI 1 Cohort

Variable
Age, y
Female
BMI, kg/m2
Disease duration, y a
Prior hospitalization
Baseline EIM
Previous TNF
antagonist
exposure
Previous TNF
antagonist failure
Concomitant CS only
Concomitant IMMs
only
Baseline endoscopy
moderate
Baseline partial Mayo
score
Baseline calprotectin,
mg/kg
Baseline albumin, g/L
VDZ maintenance q4

Short disease
duration (<2 y)
(n ¼ 126)
33
50
23
1.2
65
37
48

(25–51)
(40)
(21–27)
(0.7–1.5)
(52)
(29)
(38)

Long disease
duration (2 y)
(n ¼ 492)
40
205
24
6.2
145
177
263

(31–49)
(42)
(22–28)
(3.7–10.5)
(29)
(36)
(53)

44 (35)

222 (45)

73 (58)
41 (33)

252 (51)
171 (35)

63 (50)

214 (44)

6 (5–7)

6 (5–7)

952 (305–1800)

832 (355–1727)

36 (33–41)
105 (83)

37 (34–40)
391 (79)

BMI, body mass index; CS, corticosteroid; EIM, extraintestinal manifestation;
IMM, immunomodulator; q, quartile; TNF, tumor necrosis factor.
a
2 patients had missing data for disease duration.
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Supplementary Table 4. Differences in Median Measured VDZ Concentrations Over 52 Weeks in GEMINI 1 Trial Derivation Cohort

Time point

93.8
22.9
112
33.8
17.2
108
15.7
17.95
109
16.9
22.5
108
35.25

0
(78.7–108)
(17.6–29.2)
(94.9–132)
(25.5–45.4)
(10.5–25.2)
(89.8–128)
(7.79–24.1)
(9.27–29.8)
(91.55–129.5)
(7.59–32.7)
(7.97–36.4)
(91.3–129)
(19.6–60.65)

Intermediate
probability (mg/mL)
92.6
27.4
115.5
42.25
23.5
113
21.25
23.8
112.5
26.3
27.8
115
43.1

0
(78–108)
(23.3–35.7)
(96.2–139)
(33.1–53.6)
(16.85–33.3)
(93.9–136)
(12.9–32.7)
(13.5–37.55)
(94.6–142)
(13.7–42.6)
(13.6–42.8)
(90–143)
(20.5–63.1)

High probability
(mg/mL)
98.3
32
129.5
53.8
34.85
126
29.45
32.45
125
29.5
31.5
127
52.25

Values are median (interquartile range). All postdose assessments were done 2 hours postdose.
VDZ, vedolizumab.
a
Closed test procedure used to control for type I error.

0
(80.4–117)
(26.6–39.5)
(108–149.5)
(41.4–64.5)
(25.9–43.6)
(102–150)
(18–43.5)
(17.55–48.1)
(103–145)
(15.9–50.2)
(14.1–52.3)
(104–153)
(21.1–77.6)

P value (overall)

P value
(low vs intermediate)

P Value
(Low vs High)

P Value
(Intermediate
vs High)

—
.095
<.001a
<.001a
<.001a
<.001a
<.001a
<.001a
<.001a
.032a
.002a
.015a
.016a
.053

—
.842
<.001a
.593
<.001a
<.001a
.062
<.001a
.007a
.285
.010a
.069
.368
.498

—
.103
<.001a
<.001a
<.001a
<.001a
<.001a
<.001a
<.001a
.009a
<.001a
.005a
.008a
.028a

—
.034a
<.001a
<.001a
<.001a
<.001a
<.001a
<.001a
.004a
.059
.154
.104
.023a
.050
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Baseline predose
Baseline postdose
Week 2 predose
Week 2 postdose
Week 4
Week 6 predose
Week 6 postdose
Week 14
Week 22 predose
Week 22 postdose
Week 38
Week 46 predose
Week 46 postdose
Week 52

Low probability
(mg/mL)
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Supplementary Table 5. Differences in Partial Mayo Score Over 52 Weeks in GEMINI 1 Trial Derivation Cohort
Intermediate probability;
Low probability; mean
mean change from
change from baseline baseline (interquartile
Time point
(interquartile range)
range)
Baseline
Week 2
Week 4
Week 6
Week 10
Week 14
Week 18
Week 22
Week 26
Week 30
Week 34
Week 38
Week 42
Week 46
Week 50
Week 52

–0.67
–1.18
–1.38
–1.81
–2.19
–2.44
–3.04
–3.15
–3.29
–3.26
–3.52
–3.74
–3.92
–3.94
–3.88

0
(–1.0
(–2.0
(–2.0
(–3.0
(–4.0
(–4.0
(–4.0
(–5.0
(–5.0
(–5.0
(–5.0
(–5.0
(–5.0
(–5.0
(–6.0

to
to
to
to
to
to
to
to
to
to
to
to
to
to
to

0.0)
0.0)
0.0)
0.0)
–1.0)
–1.0)
–1.0)
–2.0)
–1.0)
–1.0)
–2.0)
–2.0)
–2.0)
–2.0)
–2.0)

–0.98
–1.71
–1.88
–2.31
–2.51
–2.74
–3.16
–3.45
–3.75
–4.06
–4.22
–4.28
–4.30
–4.45
–4.44

0
(–2.0
(–3.0
(–3.0
(–4.0
(–4.0
(–4.0
(–5.0
(–5.0
(–6.0
(–6.0
(–6.0
(–6.0
(–6.0
(–6.0
(–6.0

to
to
to
to
to
to
to
to
to
to
to
to
to
to
to

0.0)
0.0)
0.0)
0.0)
–1.0)
–1.0)
–1.0)
–2.0)
–2.0)
–2.0)
–3.0)
–3.0)
–3.0)
–3.0)
–3.0)

High probability;
mean change
P
from baseline
P value
value
P value
(interquartile P value
(low vs
(low vs (intermediate
range)
(overall) intermediate) high)
vs high)
–1.11
–1.91
–2.08
–2.73
–3.06
–3.23
–3.55
–3.77
–3.75
–3.77
–3.95
–4.16
–4.14
–4.18
–4.17

0
(–2.0
(–3.0
(–3.0
(–4.0
(–4.0
(–5.0
(–5.0
(–5.0
(–5.0
(–5.0
(–6.0
(–6.0
(–6.0
(–6.0
(–6.0

to
to
to
to
to
to
to
to
to
to
to
to
to
to
to

0.0)
0.0)
–1.0)
–1.0)
–2.0)
–2.0)
–2.0)
–2.0)
–3.0)
–2.0)
–3.0)
–3.0)
–3.0)
–3.0)
–3.0)

—
.003a
<.001a
<.001a
<.001a
<.001a
<.001a
.003a
.002a
.004a
<.001a
.002a
.015a
.074
.145
.029a

—
.007a
.001a
.002a
.007a
.027a
.050
.064
.030a
.004a
<.001a
<.001a
.006a
.037a
.056
.009a

—
.001a
<.001a
<.001a
<.001a
<.001a
<.001a
<.001a
<.001a
.002a
<.001a
.004a
.010a
.035a
.098
.031a

—
.230
.134
.135
.021a
.003a
.005a
.028a
.055
.509
.805
.732
.937
.812
.853
.702

a

Closed test procedure used to control for type I error.

Supplementary Table 6. Model Performance in GEMINI 1 Trial Derivation Cohort
Cutoff

Sensitivity
(95% CI) (%)

Speciﬁcity
(95% CI) (%)

PPV (95% CI)

NPV (95% CI)

Positive LR (95% CI)

Negative LR (95% CI)

26 points
32 points

87.5 (81.8–91.9)
34.2 (27.4–41.6)

28.1 (23.9–32.6)
82.5 (78.6–85.9)

34.0 (29.8–38.5)
45.3 (36.9–54.0)

84.1 (77.2–89.7)
74.7 (70.6–78.6)

1.22 (1.12–1.32)
1.96 (1.47–2.60)

0.44 (0.29–0.67)
0.80 (0.71–0.89)

Area under the receiver-operating characteristic curve 0.65, Brier score 0.18, Nagelkerke R-square 0.07, Hosmer-Lemeshow goodness-of-ﬁt P value ¼ .46.
CI, conﬁdence interval; LR, likelihood ratio; NPV, negative predictive value; PPV, positive predictive value.
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Supplementary Table 7. Anti-TNF–Treated UC Patients
Anti-TNF Cohort
(n ¼ 123)
Female
Smoker (never)
Age, y
Body mass index, kg/m2
Disease duration, y
Disease duration <2 y
Prior hospitalization
Prior TNF antagonist exposure
Prior TNF antagonist failure
Extensive baseline disease
Baseline moderate endoscopic disease
Baseline albumin, g/L

57 (46)
85 (69)
37.7  15.7
25.4  7.8
3 (1–9)
84 (68)
72 (58)
41 (33)
27 (22)
83 (68)
54 (44)
3.6  0.6

Values are n (%), mean  SD, or median (interquartile range).
TNF, tumor necrosis factor; UC, ulcerative colitis.

